Skinvisible Provides Update on Proposed Merger with Quoin Pharmaceuticals
Mar 26, 2018 20:05 pm UTC| Business
LAS VEGAS, March 26, 2018 -- via NetworkWire - Skinvisible, Inc. (“Skinvisible”) (OTCQB:SKVI), is pleased to announce the signing of a merger agreement with Quoin Pharmaceuticals, Inc. (“Quoin”) subject to tax,...
StoneMor Partners Appoints Patricia D. Wellenbach and Stephen J. Negrotti to Board of Directors
Mar 26, 2018 20:05 pm UTC| Business
TREVOSE, Pa., March 26, 2018 -- StoneMor Partners L.P. (NYSE:STON) (“StoneMor” or the “Partnership”), a leading owner and operator of cemeteries and funeral homes, today announced that Allen Freedman and Howard Carver...
Sol-Gel Technologies Ltd. Availability of Its Annual Report on Form 20-F Through Its Website
Mar 26, 2018 20:05 pm UTC| Business
NESS ZIONA, Israel, March 26, 2018 -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company, announced today that it filed its Annual Report for 2017 on Form 20-F, containing audited financial...
Mar 26, 2018 20:05 pm UTC| Business
NEW YORK, March 26, 2018 -- At the end of the settlement date of March 15, 2018, short interest in 2,331 Nasdaq Global MarketSM securities totaled 7,230,277,603 shares compared with 7,052,302,122 shares in 2,345 Global...
Bimini Capital Management Announces Share Repurchase Plan
Mar 26, 2018 20:05 pm UTC| Business
VERO BEACH, Fla., March 26, 2018 -- Bimini Capital Management, Inc. (OTCQB:BMNM) ("Bimini” or the "Company"), announced today that its Board of Directors approved a plan to repurchase up to 500,000 shares of the...
Mar 26, 2018 20:05 pm UTC| Business
JERSEY, Channel Islands, March 26, 2018 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the retirement of Paul Cowan as its Chairman and Chief Executive Officer. Franz Walt,...
Mar 26, 2018 20:05 pm UTC| Business
46% of adult peanut allergy patients with moderate-to-severe baseline symptoms tolerated 500mg cumulative peanut challenge at 14 days after a single dose of ANB020 compared to zero percent dosed with placeboConcomitant...